Alnylam Presents Preclinical In Vivo on RSF Drug Candidate

Alnylam said last week that it presented in vivo efficacy data for its lead RNAi therapeutic candidate for respiratory syncytial virus at the annual meeting of the American Academy of Allergy, Asthma, and Immunology in San Antonio, Texas.

According to the company, the data demonstrated that a single low dose of an optimized siRNA, called ALN-RSV01, inhibited RSV replication both as a prophylactic and as a treatment when administered by intranasal delivery in a liquid form.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.